Fred Beasley, PhD
Field Applications Scientist, Taconic Biosciences
Dr. Beasley’s academic training is in environmental microbiology, bacterial diseases, and host-pathogen responses. He completed his PhD at Canada’s Western University, researching iron uptake during invasive Staphylococcus aureus infection. He relocated to Southern California for postdoctoral work.
At UC San Diego, he developed animal models to evaluate boosting the innate immune system by modulating the host hypoxic response, toward combating blood and urinary tract bacterial infection. At Calibr/The Scripps Research Institute, he ran the in vivo program for early pipeline validation of small molecule drugs against parasitic diseases including malaria, cryptosporidiosis, and filarial nematode diseases.
Dr. Beasley forayed into metabolic disease research as an in vivo biologist with the inflammation and NASH startup biotech Jecure Therapeutics, and later served as the Director of Scientific Engagement for cardiovascular and metabolic disease at Crown Bioscience.
Fred joined Taconic in 2020 as the Field Application Scientist servicing the Western regions of the USA and Canada.
At UC San Diego, he developed animal models to evaluate boosting the innate immune system by modulating the host hypoxic response, toward combating blood and urinary tract bacterial infection. At Calibr/The Scripps Research Institute, he ran the in vivo program for early pipeline validation of small molecule drugs against parasitic diseases including malaria, cryptosporidiosis, and filarial nematode diseases.
Dr. Beasley forayed into metabolic disease research as an in vivo biologist with the inflammation and NASH startup biotech Jecure Therapeutics, and later served as the Director of Scientific Engagement for cardiovascular and metabolic disease at Crown Bioscience.
Fred joined Taconic in 2020 as the Field Application Scientist servicing the Western regions of the USA and Canada.